Nattokinase vs Vesugen
A side-by-side research comparison of Nattokinase and Vesugen across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Nattokinase | Vesugen |
|---|---|---|
| Full name | Nattokinase (Subtilisin NAT) | Vesugen (Lys-Glu-Asp Vascular Bioregulator) |
| Category | Cardiovascular | Cardiovascular |
| Status | Dietary supplement | Research compound (peptide bioregulator) |
| Mechanism | Directly degrades fibrin in blood clots via proteolytic activity. Also activates endogenous tissue plasminogen activator (tPA) and suppresses plasminogen activator inhibitor-1 (PAI-1), enhancing the body's own fibrinolytic system. | As a signal peptide (Lys-Glu-Asp), it is proposed to enter cells and regulate gene expression in vascular tissue, supporting endothelial function, vascular tone, and normal vessel-wall maintenance. |
| Molecular weight | ~27,728 Da | ~390 Da |
| Half-life | ~8-12 hours (fibrinolytic activity) | Short (peptide) |
| Bioavailability | Oral absorption confirmed; survives GI tract | Oral (encapsulated) or subcutaneous |
| Typical dose | 2000-4000 FU (fibrinolytic units) | ~1-2 capsules/day or short injectable courses |
| Frequency | Daily on empty stomach | Once daily |
| Route | Oral capsule | Oral capsule or subcutaneous |
Nattokinase reported benefits
- Fibrin clot dissolution
- Blood pressure reduction
- Improved blood viscosity
- Reduced DVT risk
- Atherosclerosis prevention
- Natural anticoagulant alternative
Vesugen reported benefits
- Vascular/endothelial support
- Proposed vascular tissue regulation
- Short course-based protocol
- Part of bioregulator longevity systems
Related comparisons
Research and educational reference only. Not medical advice.